Massimo Dominici, University of Modena and Reggio Emilia, Modena/I
Optimizing performance and quality of mesenchymal progenitors for better regeneration
Dorothee Holm-von Laer, Innsbruck Medical University/A
Oncolytic virus vaccine: An emerging class of ATMPs
Ulrich Kalinke, Hannover Medical School / TWINCORE GmbH, Hanover/D
Pre-clinical requirements for (gene) cell therapies
Mark W. Lowdell, Royal Free London NHS FT & University College London/UK
Title t.b.a.
Ineke Slaper-Cortenbach, University Medical Center Utrecht/NL
Quality controls for ATMP-products in the regulatory framework: what is mandatory?
Christian van den Bos, Mares Ltd., Greven/D
From manufacturing clinical trial samples towards producing commercial quantities: challenges, tools and perspectives
Jaana Vesterinen, Finnish Medicines Agency Fimea, Helsinki/FI
Quality of raw materials for the production of ATMPs: Ph Eur recommendations